Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib
The discovery of anaplastic lymphoma kinase (ALK) tyrosine kinase gene rearrangement mutations in non-small cell lung cancer (NSCLC) has driven continuous advancements in ALK-targeted therapies. The next generation of ALK tyrosine kinase inhibitor, Brigatinib, has demonstrated significant efficacy i...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Chinese |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2025-06-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2025.106.12 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The discovery of anaplastic lymphoma kinase (ALK) tyrosine kinase gene rearrangement mutations in non-small cell lung cancer (NSCLC) has driven continuous advancements in ALK-targeted therapies. The next generation of ALK tyrosine kinase inhibitor, Brigatinib, has demonstrated significant efficacy in patients with ALK-positive NSCLC, offering clinical benefits in deep response of tumor, treatment of brain metastases patients, quality of life, and long-term survival. This review will provide current advancements and exploratory directions for Brigatinib. |
|---|---|
| ISSN: | 1009-3419 1999-6187 |